Detail akcie PharmaCyte Biot Rg online

Business Summary: PharmaCyte Biotech, Inc. is a biotechnology company, which is focused on developing cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.
Financial Summary: BRIEF: For the six months ended 31 October 2025, Pharmacyte Biotech Inc revenues was not reported. Net loss applicable to common stockholders totaled $16.8M vs. income of $14.2M. Net loss reflects Gain on related party investment - QCLS decrease of 90% to $2.1M (income), Change in fair value of warrant liabilit decrease from $3.9M (income) to $10.2M (expense), Fair Value Adjustments on Other Assets decrease of 86% to $302K (income).